PURPOSE: To determine the risk of subsequent carcinomas other than breast, thyroid, and skin, and to identify factors that influence the risk among survivors of childhood cancer. PATIENTS AND METHODS: Subsequent malignant neoplasm history was determined in 13,136 participants (surviving > or = 5 years postmalignancy, diagnosed from 1970 to 1986 at age < 21 years) of the Childhood Cancer Survivor Study to calculate standardized incidence ratios (SIRs), using Surveillance, Epidemiology, and End Results data. RESULTS: In 71 individuals, 71 carcinomas were diagnosed at a median age of 27 years and a median elapsed time of 15 years in the genitourinary system (35%), head and neck area (32%), gastrointestinal tract (23%), and other sites (10%). Fifty-nine patients (83%) had received radiotherapy, and 42 (59%) developed a second malignant neoplasm in a previous radiotherapy field. Risk was significantly elevated following all childhood diagnoses except CNS neoplasms, and was highest following neuroblastoma (SIR = 24.2) and soft tissue sarcoma (SIR = 6.2). Survivors of neuroblastoma had a 329-fold increased risk of renal cell carcinomas; survivors of Hodgkin's lymphoma had a 4.5-fold increased risk of gastrointestinal carcinomas. Significantly elevated risk of head and neck carcinoma occurred in survivors of soft tissue sarcoma (SIR = 22.6), neuroblastoma (SIR = 20.9), and leukemia (SIR = 20.9). CONCLUSION: Young survivors of childhood cancers are at increased risk of developing subsequent carcinomas typical of later adulthood, underscoring the importance of long-term follow-up and risk-based screening. Follow-up of the cohort is ongoing to determine lifetime risk and delineate individual characteristics that contribute to risk.
PURPOSE: To determine the risk of subsequent carcinomas other than breast, thyroid, and skin, and to identify factors that influence the risk among survivors of childhood cancer. PATIENTS AND METHODS: Subsequent malignant neoplasm history was determined in 13,136 participants (surviving > or = 5 years postmalignancy, diagnosed from 1970 to 1986 at age < 21 years) of the Childhood Cancer Survivor Study to calculate standardized incidence ratios (SIRs), using Surveillance, Epidemiology, and End Results data. RESULTS: In 71 individuals, 71 carcinomas were diagnosed at a median age of 27 years and a median elapsed time of 15 years in the genitourinary system (35%), head and neck area (32%), gastrointestinal tract (23%), and other sites (10%). Fifty-nine patients (83%) had received radiotherapy, and 42 (59%) developed a second malignant neoplasm in a previous radiotherapy field. Risk was significantly elevated following all childhood diagnoses except CNS neoplasms, and was highest following neuroblastoma (SIR = 24.2) and soft tissue sarcoma (SIR = 6.2). Survivors of neuroblastoma had a 329-fold increased risk of renal cell carcinomas; survivors of Hodgkin's lymphoma had a 4.5-fold increased risk of gastrointestinal carcinomas. Significantly elevated risk of head and neck carcinoma occurred in survivors of soft tissue sarcoma (SIR = 22.6), neuroblastoma (SIR = 20.9), and leukemia (SIR = 20.9). CONCLUSION: Young survivors of childhood cancers are at increased risk of developing subsequent carcinomas typical of later adulthood, underscoring the importance of long-term follow-up and risk-based screening. Follow-up of the cohort is ongoing to determine lifetime risk and delineate individual characteristics that contribute to risk.
Authors: Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan Journal: Ann Intern Med Date: 2012-06-05 Impact factor: 25.391
Authors: Karen Tsui; Amar Gajjar; Chenghong Li; Deokumar Srivastava; Alberto Broniscer; Cynthia Wetmore; Larry E Kun; Thomas E Merchant; David W Ellison; Brent A Orr; Frederick A Boop; Paul Klimo; Jordan Ross; Leslie L Robison; Gregory T Armstrong Journal: Neuro Oncol Date: 2014-11-13 Impact factor: 12.300
Authors: Sarah B Scarboro; Marilyn Stovall; Allen White; Susan A Smith; Derek Yaldo; Stephen F Kry; Rebecca M Howell Journal: Phys Med Biol Date: 2010-11-12 Impact factor: 3.609
Authors: Sharon M Castellino; Ann M Geiger; Ann C Mertens; Wendy M Leisenring; Janet A Tooze; Pam Goodman; Marilyn Stovall; Leslie L Robison; Melissa M Hudson Journal: Blood Date: 2010-10-29 Impact factor: 22.113
Authors: Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice Journal: J Natl Cancer Inst Date: 2012-02-06 Impact factor: 13.506
Authors: Emily L B Lykins; Lili O Graue; Emily H Brechting; Abbey R Roach; Celestine G Gochett; Michael A Andrykowski Journal: Psychooncology Date: 2008-10 Impact factor: 3.894
Authors: Natalie A Lockney; Danielle Novetsky Friedman; Leonard H Wexler; Charles A Sklar; Dana L Casey; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2016-05-16 Impact factor: 3.167